General Information of Drug (ID: DMKEIAS)

Drug Name
CTLA-4-XTEN Drug Info
Synonyms Cytotoxic T-lymphocyte protein 4 modulator (XTEN, rheumatoid arthritis/transplant rejection), Amunix
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Investigative [1]
Cross-matching ID
TTD Drug ID
DMKEIAS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ipilimumab DMJTIYK Melanoma 2C30 Approved [2]
Tremelimumab DMOQ9H1 Hepatocellular carcinoma 2C12.02 Approved [1]
KN046 DMSDBPG Non-small-cell lung cancer 2C25.Y Phase 3 [3]
AK04 DMU7K86 Actinic keratosis EK90.0 Phase 3 [4]
AK104 DMXJ8Z4 Cervical cancer 2C77.0 Phase 2 [5]
Lorigerlimab DM2E8Z5 Prostate cancer 2C82.0 Phase 2 [6]
Vudalimab DMSEEI0 Prostate cancer 2C82.0 Phase 2 [7]
AGEN1884 DMAP5B4 Cervical cancer 2C77.0 Phase 1/2 [8]
BMS-986288 DMM10J4 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [9]
MK-1308 DM25QKC Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Modulator [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
2 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
3 Clinical pipeline report, company report or official report of Alphamab Oncology.
4 A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
5 Clinical pipeline report, company report or official report of Akeso Biopharma.
6 Clinical pipeline report, company report or official report of MacroGenics
7 Clinical pipeline report, company report or official report of Xencor
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of CytomX Therapeutics.
10 Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.